UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 148
- Registration Number
- NCT01330290
- Locations
- 🇩🇪
40, Gelsenkirchen, Germany
🇩🇪28, Hamm, Germany
🇩🇪24, Berlin, Germany
Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 349
- Registration Number
- NCT01300819
- Locations
- 🇧🇬
49, Sofia, Bulgaria
🇨🇭26, Sargans, Switzerland
🇨🇿222, Ostrava-Poruba, Czech Republic
A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 3
- Registration Number
- NCT01292265
- Locations
- 🇺🇸
1, Voorhees, New Jersey, United States
🇺🇸10, Los Angeles, California, United States
🇺🇸4, Walnut Creek, California, United States
Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients
Completed
- Conditions
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 149
- Registration Number
- NCT01288287
- Locations
- 🇮🇪
2, Cork, Ireland
🇬🇧24, Eastbourne, East Sussex, United Kingdom
🇬🇧17, Poole, Dorset, United Kingdom
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2012-03-22
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 67
- Registration Number
- NCT01276119
Prostaglandin E1 in Outpatients With Intermittent Claudication
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 561
- Registration Number
- NCT01263925
Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT01262794
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 793
- Registration Number
- NCT01262365
- Locations
- 🇧🇷
455, Campinas, Brazil
🇺🇸031, Los Angeles, California, United States
🇺🇸040, Baltimore, Maryland, United States
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 791
- Registration Number
- NCT01261793
- Locations
- 🇭🇺
715, Szeged, Hungary
🇮🇹648, Milano, Italy
🇮🇹646, Roma, Italy
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 768
- Registration Number
- NCT01261325
- Locations
- 🇺🇸
090, Ocala, Florida, United States
🇺🇸006, Tucson, Arizona, United States
🇺🇸044, Sarasota, Florida, United States
© Copyright 2024. All Rights Reserved by MedPath